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Abstract
Vaccines are a very effective tool for the prevention and eradication of 
infective diseases in both veterinary and human medicine. Although for 
safety reasons, vaccines undergo very strict controls before being placed on 
the market, the risk of adverse reactions is not eliminated. According to the 
World Health Organization (WHO), adverse event following immuniza-
tion (AEFI) is any untoward medical occurrence that follows immunization 
and which does not necessarily have a causal relationship with the usage 
of the vaccine. Adverse reactions may arise as a direct consequence of im-
munization due to the specificity of the vaccine itself, the quality of the 
vaccine or the immunization errors. In addition, adverse reactions may also 
be the result of a coincidental relationship between the effect and immuni-
zation. However, biological mechanisms of AEFI are very complex. During 
the mass vaccination campaigns, when a large number of animals are vac-
cinated in a short period of time, adverse reactions are expected to be the 
most frequently reported. In Serbia, livestock is currently being vaccinated 
against Lumpy Skin Disease, Bluetongue, and Classical swine fever. 
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Kratak sadržaj
Vakcine su veoma efikasan alat za prevenciju i iskorenjivanje infektivnih 
bolesti u veterinarskoj i humanoj medicini. Iako iz sigurnosnih razloga 
vakcine prolaze kroz vrlo stroge kontrole pre stavljanja u promet, rizik od 
neželjenih reakcija nije eliminisan. Prema Svetskoj zdravstvenoj organizaciji 
(SZO), neželjeni događaj nakon imunizacije je svaka neugodna medicinska 
pojava koja prati imunizaciju i koja ne mora nužno imati uzročnu vezu sa 
upotrebom vakcine. Neželjene reakcije mogu nastati kao direktna posledica 
imunizacije usled specifičnosti same vakcine, kvaliteta vakcine ili grešaka 
prilikom imunizacije. Pored toga, neželjene reakcije mogu biti i posledica 
slučajnog odnosa između nastalog efekta i imunizacije. Međutim, biološki 
mehanizmi nastanka ovih reakcija su veoma složeni. Tokom kampanja mas-
ovnih vakcinacija, kada se veliki broj životinja vakciniše u kratkom vremen-
skom periodu, očekuje se da se neželjene reakcije najčešće prijavljuju. U 
Srbiji se stoka trenutno vakciniše protiv bolesti kvrgave kože, bolesti plavog 
jezika i klasične svinjske kuge. Pošto nijedna od ove tri vakcine nije DIVA, 
praćenje neželjenih događaja koji se mogu pojaviti je od izuzetnog značaja. 
Ključne reči: vakcina, neželjena reakcija, masovna vakcinacija
INTRODUCTION
Vaccines are a very effective tool for the prevention and eradication of in-
fective diseases in both veterinary and human medicine. Vaccines are, also, 
used to improve the welfare of companion animals as well as to treat the non-
infectious diseases such as allergies or cancer, even to increase production and 
fertility of livestock (Meeusen et al., 2007). Immuno-contraception of pests 
is also based on vaccine use (Hardy et al, 2006). Effects of vaccinations are 
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remarkable and measurable, particularly with regard to the cost. Thanks to 
the massive vaccination, among the other applied measures, the Rinderpest 
was declared as eradicated worldwide by the OIE and FAO in May and June 
2011 (Roeder et al, 2013). Classical swine fever (CSF) has been successfully 
eradicated from some countries including EU member states, Canada, United 
States, Australia and New Zealand, where the use of the vaccine was of the 
highest contribution (Greiser-Wilke and Moening, 2004). World Health Or-
ganization (WHO, 2018) announces the elimination of human rabies trans-
mitted by dogs by 2030 through the affordable human vaccines and antibodies 
and mass dog vaccination supported by increased communication, awareness 
and education.
Today, in veterinary medicine, the most used vaccines are modified live 
vaccines (MLV), killed (KV), and toxoid type vaccines, each characterized by 
advantages and disadvantages. While live vaccines typically stimulate more 
rapid, stronger, and longer-lasting immunity than killed vaccines, using the 
killed vaccines there is no risk of the vaccine organism spreading between ani-
mals as well as the risk of causing abortion is minimal (Jorge and Dellagostin, 
2017). MLVs are mainly available for diseases caused by viruses, such as bo-
vine herpesvirus 1, bovine viral diarrhea virus (BVDV), bovine respiratory 
syncytial virus (BRSV), and parainfluenza-3 virus (Pl3). KVs usually contain 
adjuvants, or added substances, that further stimulate the immune system to 
respond to the vaccine challenge. Even more, the majority of KVs are safe to 
use in any animal, including pregnant ones (Jorge and Dellagostin, 2017).
Apart from the vaccine formulation, the administration route and the 
method of vaccination influence on the efficacy and safety of a vaccine.
Usually, in the veterinary medicine, the vaccines are administered paren-
terally via intramuscular, subcutaneous and intradermal injection. The mu-
cosal immunization includes intraocular, intranasal and/or oral administra-
tion. Mucosal application of attenuated vaccines via drinking water or spray, 
being very successful, is now routinely applied in poultry (Makoschey, 2015). 
The oral administration of rabies vaccine in vaccination of wild carnivores has 
had a great contribution to the rabies control and eradication (Lupulović et al, 
2015). Oral vaccine for classical swine fever, after having been used since years 
for the CSF control and eradication of CSF in wild boar, is now recommended 
for domestic pigs vaccination, particularly for those kept extensively, in back-
yards (Milićević et al., 2013; Dietze et al., 2013).
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ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI)
Although for safety reasons, vaccines undergo very strict controls before 
being placed on the market, the risk of adverse reactions is not eliminated. 
According to the World Health Organization (WHO, 2018), adverse event fol-
lowing immunization is any untoward medical occurrence that follows im-
munization and which does not necessarily have a causal relationship with the 
usage of the vaccine. 
AEFIs are grouped into five categories: vaccine product-related reaction, 
vaccine quality defect-related reaction, immunization error-related reaction, 
immunization anxiety-related reaction and coincidental event (WHO, 2018). 
Biological mechanisms of AEFI are very complex. Very often, the latency 
between antigen exposure and peak adaptive immune response, due to the 
adjuvants that help to increase the response rates to vaccines, results in pro-
longed exposure of the immune system cells to antigen and consequently the 
release of inflammatory mediators. Further on, the tissue damage or clinical 
disease occurrence following the immunization could be related to some of the 
immune-mediated mechanisms such as effector functions of T cells, effector 
functions of antibodies and autoantibodies, complement activation, hypersen-
sitivity reactions etc. (Stratton, 2012).
Attenuated live viral vaccines can cause the same effects through the same 
mechanisms like it happens during the natural infection. Such events occur 
usually when the immune system is impaired or the animal immunocompro-
mised. Some of the adverse events, like complex regional pain syndrome, syn-
cope etc., are not directly related to the contents of the vaccine but rather to the 
adverse event of direct trauma from the needle (Stratton, 2012). 
AEFIs can be manifested as either local or systemic reactions. Minor lo-
cal reactions include pain, redness and swelling at the injection site within 48 
hours of vaccination. Such reactions that extend past the nearest joint and/or 
persisting for 10 days or more should be reported (WHO, 2018). Arthus Reac-
tion is a major local reaction manifested with 48 hours after the immunization 
as a large, localized reaction characterized by pain, swelling, induration, and 
edema. This reaction usually occurs when there is a large number of circulat-
ing antibodies prior to injection of the antigen. Most Arthus reactions resolve 
within one week. Abscess at the injection site is a swollen lump, fluid-filled, be-
coming very painful which usually appears within 7 days after immunization 
due to the bacterial contamination. The sterile abscess can persist for more 
than 1 month. Nodules are solid, elevated areas of tissue at the injection site 
with discrete or well-demarcated borders. Normally, nodules are not accom-
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panied either with abscess formation, erythema or warmth. They are mainly 
caused by aluminum-based adjuvants and subcutaneous route of administra-
tion. Sterile nodules can take up to 1 year or more to resolve. 
Cellulitis at the injection site is an acute inflammation of the subcutaneous 
tissue, fat, fascia or muscle, usually seen within 7 days after vaccine adminis-
tration due to the bacterial contamination (WHO, 2018). 
Fever is the most often seen systemic reaction. It appears within 72 hours 
when killed vaccines are used, while this time is prolonged with the live vac-
cines. A fever that begins within 24 hours after vaccination with the inacti-
vated vaccine or persists for more than 24 hours after vaccination should not 
be assumed to be due to the vaccine (WHO, 2018). 
The enlargement of one or more lymph nodes is usually associated with 
some adjuvants that produce transient chemokine and cytokine stimulation, 
enhanced the local activity of antigen presenting cells, and uptake by regional 
lymph nodes. However, the live vaccines, due to a low-grade infection, can 
cause the adenopathy (WHO, 2018). 
Allergic reactions are an acquired hypersensitivity to a component of the 
vaccine. They are usually manifested as a mild form of the dermatological/mu-
cosal and/or the respiratory systems disorders. Allergic reactions occur within 
48 hours of immunization. However, anaphylaxis, a type of allergic reaction, 
is the potentially life-threatening adverse reaction to the immunization. It is 
manifested by sudden onset, rapid progression of signs and symptoms and 
involvement of multiple organ systems (WHO, 2018). 
Many other reactions such as neurological disorders, thrombocytopenia, 
arthritis etc., can also be related to the immunization.
In the veterinary medicine, the most common side effects include transient 
swelling at the site of injection and a reaction that may change coat color in 
the area, transient pyrexia, respiratory distress, salivation, vomiting, diarrhea, 
urticaria, reduced fertility, fetal deformities and abortion (Morton, 2007). 
However, immune-mediated hemolytic anemia (IMHA), thrombocytopenia 
(IMTP), polyneuritis and polyarthritis are autoimmune disorders (primarily 
in the dog) that can, also, be linked to vaccination (Day, 2006). Hypersensitiv-
ity type III where the cutaneous vasculopathy occurs has been reported fol-
lowing rabies virus vaccination. Similarly, the formation and the deposition 
of immune complexes are the cause of adenoviral-related ‘blue eye’ in dogs. 
As a different category of adverse events, Day (2006) states the lack of efficacy 
although it is more often due to the inappropriate administration, or adminis-
tration to immunosuppressed or immunodeficient individuals than to batches 
of subnormal efficacy. The effects that can occur due to the residual virulence 
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of attenuated vaccine strains, or batch contamination during manufacture are 
also considered as adverse events (Day, 2006).
MASS VACCINATION CAMPAIGNS IN SERBIA
In Serbia, livestock is currently being vaccinated against Lumpy Skin Dis-
ease, Bluetongue, and Classical swine fever. During the mass vaccination cam-
paigns, when a large number of animals are vaccinated in a short period of 
time, adverse reactions are expected to be the most frequently reported.
BLUETONGUE DISEASE VACCINATION
Vaccination against bluetongue disease has been implemented in Euro-
pean countries after the incursion of the disease in 1998 (Niedbalski, 2011). 
At that time, modified live vaccines were commercially available and used for 
mass vaccination of cattle and sheep. Besides the high level of immunogenicity 
and protection, it has been shown that modified live vaccine caused significant 
side reactions. Adverse events such as fever, facial oedema, lameness, reduced 
milk production, and teratogenicity were reported mostly in sheep. Abortions 
were recorded in less than 0.5% of vaccinated animals (Savini et al., 2008b). 
Those reactions are commonly attributed to under-attenuation of the modified 
strains and their capacity of passing the placental barrier, and the spread of vac-
cine strain in the environment with the potential for reversion to virulence and 
re-assortment with field isolates (Savini et al., 2008a). It has been shown that 
viremia of attenuated vaccine strain lasts up to 35 days, even reaching a titer 
which enables infection of Culicoides (Savini et al., 2008b). Circulation of vac-
cine strains has been confirmed in the Netherlands (BTV6), Germany (BTV6), 
Belgium (BTV11), and BTV14 in Lithuania, Latvia, Poland, and Estonia1. De 
Leeuw et al. (2015) also reported the possible detection of RNA in circulation 
after vaccination against BTV8. The severity of adverse events depends also on 
BTV genotype. BTV16 in attenuated vaccines produced the most severe reac-
tions (Savini et al., 2008b). Inactivated vaccines have, also, been commercial-
ized, initially against BTV2 and BTV4, but afterward for all circulating strains 
in EU (Wilson and Mellor, 2009). Thus, the risk of adverse events following 
immunization with MLV was minimized. However, for the full protection and 
prevention of both clinical symptoms and viremia, two doses of inactivated 
vaccines are needed (Savini et al., 2008a). Many studies carried out to evalu-
ate the safety of inactivated vaccines demonstrated well tolerance and absence 
1 https://ec.europa.eu/food/animals/animal-diseases/control-measures/bluetongue_en
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of the systemic reaction (fever, weight loss, reproductive dysfunction) related 
to vaccination. However, some animals developed transient local reactions of 
variable severity with a different frequency (Savini et al., 2008a) which usually 
disappeared within 3 days. In a single case, a moderate local reaction persisted 
for 2 weeks (Hamers et al., 2006). Anaphylaxis was only reported in animals 
which previously received MLV. Neither side effects nor local reactions in 
safety studies for cattle have been reported even when five doses of the BTV-4 
inactivated vaccine was administered to the same animal (Savini et al., 2008a). 
Inactivated BTV4 vaccine has been used in Serbia since 2015. Expected ad-
verse events are the slight increase in body temperature and appearance of 
the nodule at the injection site. According to the manufacturer`s instruction, 
it can be expected that up to 53% of vaccinated animals display the nodules 
which should disappear within 35 days in sheep or even longer in cattle.
LUMPY SKIN DISEASE VACCINATION
Lumpy skin disease was confined to African continent until 1989 when 
occurred in Israel, for the first time outside Africa. When the disease was 
introduced in Turkey and Iraq in 2013, its potential for further spread was 
evident. By the year 2016 the virus was detected in seven European countries 
– Greece, Bulgaria, the Former Yugoslav Republic of Macedonia, Serbia, Al-
bania, Montenegro, and Kosovo. For the disease control and eradication, vac-
cination has been immediately implemented. Live attenuated vaccines are the 
most commonly used. There are currently two types of them, derived either 
from the South-African LSDV Neethling strain or an attenuated LSDV field 
strain. However, even heterologous vaccines can be used but provide incom-
plete protection. Abutarbush et al. (2016) reported that duration between vac-
cine administration and appearance of adverse clinical signs ranged from 1 to 
20 days. Clinical manifestations which included fever, decreased feed intake, 
decreased milk production and variable sized cutaneous nodules lasted from 
3 to 20 days. However, no mortalities were reported due to vaccine adverse 
reactions. Croatia reported adverse events on 0.24% of the vaccinated farms, 
involving 0.09% of the total animals affected and 0.02% deaths (EFSA, 2017). 
Commonly, the symptoms appeared within 2 weeks after vaccination and in-
cluded fever (22%), a decrease in milk production (27%), edema at injection 
site (21%), lumps (12%), erythema (7%), abortions (7%) and ataxia (5%) of af-
fected animals. Katsoulos et al. (2016) described that in Greece 12% of animals 
had the pronounced swelling at injection-site while 10% of animals developed 
small-sized skin nodules. The milk production was reduced up to 16% during 
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the first 12 days post-vaccination. Vaccine virus was detectable in blood be-
tween 6 and 15 days post vaccination as well as in aspirates obtained from the 
injection-site lesions and in nodule biopsies suggesting the need for DIVA vac-
cine. Despite the evident adverse effects, it has been shown that vaccine based 
on attenuated Neethling strain was 4.3 times more effective in preventing labo-
ratory‐diagnosed LSD than the sheep pox vaccine, and 11.2 times more effec-
tive in preventing severe LSD cases (Ben-Gera et al., 2015). Though massive 
vaccination in many countries has been implemented, there is no evidence 
of the vaccine strain regaining virulence or spreading of the disease via cattle 
products (Tuppurainen and Galon, 2016).
CLASSICAL SWINE FEVER VACCINATION
To control and eradicate classical swine fever, the safe and highly effica-
cious live attenuated vaccine based on China strain (C strain) has been used 
since years in Serbia. Apart from the traditionally used intramuscular vaccine, 
the formulation for oral administration has also been confirmed as efficient 
and safe (Milićević et al., 2013). In order to enable differentiation between vac-
cine and field strain, many other vaccines were developed. However, it has 
been shown that the best candidate is the recombinant CP7_E2alf vaccine 
(Blome et al., 2017). 
Blome et al. (2006) showed that vaccine based on attenuated C strain could 
cause no damage in vaccinated animals. The C strain was not interfered with 
gestation, though it passages through the placental barrier. Therefore the vac-
cine was safe for use in pregnant animals, even in immunosuppressed ones. 
The same authors reported that E2 subunit vaccines were also highly safe, apart 
from a possible local tissue reaction at the injection site (Blome et al., 2017).
As other, MLV for CSF is detectable for some time after vaccination. How-
ever, though the genome of the CP7_E2alf vaccine is detectable by RT-PCR in 
tonsils and lymph nodes for up to 63 days, the shedding of vaccine virus has not 
been detected. Similarly, orally vaccinated pigs did not transmit vaccine virus to 
susceptible contact animals. However, the genome of C strain virus after orally 
administered vaccine could be detected in the tonsil 21 days post-vaccination 
(dpv) (Kaden et al., 2010). Even more, the absence of leucopenia after vaccina-
tion and no increase of virulence were reported up to now (Koenig et al., 2007).
Adverse events following vaccination in veterinary medicine, particularly 
if mandatory mass vaccination is applied, are accomplished to the compensa-
tion. However, despite the reporting system is available, so far there are no 
official reports on adverse events in Serbia.
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